CAR-T cell therapy for lung cancer: Potential and perspective

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Lung cancer remains a leading cause of cancer incidence and mortality globally.
• Current immunotherapies, including targeted antibody drugs, have limitations in treating lung cancer.
• Chimeric antigen receptor (CAR)-T cell therapy, a novel adoptive immunotherapy, has shown success in hematological tumors and is emerging for solid tumors like lung cancer.

Purpose of the Study:

• To review the fundamental structure and generation of CAR-T cells.
• To summarize prevalent tumor-associated antigens targeted in lung cancer CAR-T cell therapy clinical trials.
• To identify current challenges and explore novel strategies for CAR-T cell therapy in lung cancer.

Main Methods:

• Review of existing literature on CAR-T cell therapy for lung cancer.
• Analysis of common tumor-associated antigens utilized in clinical trials.
• Discussion of challenges and emerging strategies in CAR-T cell therapy development.

Main Results:

• CAR-T cell therapy for lung cancer is hindered by a lack of specific antigens, an immunosuppressive tumor microenvironment, poor T cell infiltration, and potential off-target effects.
• Clinical application is further limited by adverse events such as cytokine release syndrome, neurotoxicity syndrome, and tumor lysis syndrome.
• Various tumor-associated antigens are being explored in ongoing clinical trials.

Conclusions:

• CAR-T cell therapy holds potential for lung cancer treatment but requires overcoming significant biological and clinical hurdles.
• Further research into novel strategies is crucial for enhancing CAR-T cell efficacy and safety in solid tumors.
• This review aims to inform future pre-clinical and clinical investigations into CAR-T cell therapy for lung cancer.